Alembic Pharma Gets USFDA Nod for Scalp Psoriasis Drug
Aug 26, 2024 17:07
Alembic Pharmaceuticals has received USFDA approval to market a generic medication for treating moderate-to-severe scalp psoriasis. The drug, Betamethasone Valerate Foam, is therapeutically equivalent to Luxiq Foam.
New Delhi, Aug 26 (PTI) Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication used to treat moderate-to-severe psoriasis of the scalp.
The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Betamethasone Valerate Foam, the drug firm said in a statement.
The approved ANDA is therapeutically equivalent to the reference listed drug product Luxiq Foam (0.12 per cent), of Norvium Bioscience, LLC (Norvium).
Betamethasone valerate foam is a topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
Shares of Alembic Pharmaceuticals on Monday ended 0.97 per cent down at Rs 1,089.90 apiece on the BSE.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.